论文部分内容阅读
目的观察评估曲美他嗪治疗冠状动脉粥样硬化性心脏病(冠心病)合并慢性充血性心力衰竭(CHF)的临床疗效。方法80例冠心病心功能不全患者随机分为治疗组和对照组,两组患者均常规应用利尿剂ACEI,β受体阻滞剂、洋地黄类药物等治疗,治疗组在常规治疗基础上加用曲美他嗪(商品名:万爽力,法国施维雅公司生产)20mg,3次/d,疗程为8周。对照组患者使用维生素B5mg,3次/d,疗程为8周作为安慰剂。观察治疗前后两组患者的左室射血分数(LVEF),6min步行距离改善情况,治疗前后C反应蛋白浓度改变。结果治疗组总有效率达82%,对照组总有效率为50%,治疗前后两组相比LVEF,6min步行距离,CRP浓度均有显著改善(P<0.01),治疗组疗效优于对照组。结论曲美他嗪治疗冠心病心力衰竭不全可提高疗效。
Objective To evaluate the clinical efficacy of trimetazidine in the treatment of coronary atherosclerotic heart disease (CHD) complicated with chronic congestive heart failure (CHF). Methods Eighty patients with coronary heart disease and cardiac insufficiency were randomly divided into treatment group and control group. The two groups were treated with diuretic ACEI, β-blockers and digitalis drugs. The treatment group was treated with routine treatment With trimetazidine (trade name: Wan Shuangli, France Shi Weiya company) 20mg, 3 times / d, treatment for 8 weeks. The control group of patients with vitamin B5mg, 3 times / d, the course of treatment for 8 weeks as a placebo. Before and after treatment, the left ventricular ejection fraction (LVEF) and the walking distance of 6 minutes were observed in both groups before and after treatment. The concentrations of C-reactive protein before and after treatment were observed. Results The total effective rate was 82% in the treatment group and 50% in the control group. Before and after treatment, LVEF and 6-minute walking distance and CRP concentration were significantly improved (P <0.01), and the curative effect in the treatment group was better than that in the control group . Conclusion Trimetazidine treatment of coronary heart disease incomplete heart failure can improve the efficacy.